



January 3, 2018

## **Karyopharm Therapeutics to Present at the 36th Annual J.P. Morgan Healthcare Conference**

NEWTON, Mass., Jan. 03, 2018 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company, today announced that Michael Kauffman, MD, PhD, Chief Executive Officer, will present at the 36<sup>th</sup> Annual J.P. Morgan Healthcare Conference on Wednesday, January 10, 2018 at 7:30 a.m. PT at the Westin St. Francis in San Francisco.

A live webcast of the event will be available on the "Events & Presentations" page in the Investors section of the Company's website at <http://investors.karyopharm.com/events.cfm>. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.

### **About Karyopharm Therapeutics**

Karyopharm Therapeutics Inc. (Nasdaq:KPTI) is a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport and related targets for the treatment of cancer and other major diseases. Karyopharm's SINE™ compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). The Company's initial focus is on seeking regulatory approval and commercialization of its lead drug candidate, oral selinexor (KPT-330). To date, over 2,200 patients have been treated with selinexor and it is currently being evaluated in several mid- and later-phase clinical trials across multiple cancer indications, including in multiple myeloma in a pivotal, randomized Phase 3 study in combination with Velcade® (bortezomib) and low-dose dexamethasone (BOSTON) and in combination with low-dose dexamethasone (STORM) and backbone therapies (STOMP), and in diffuse large B-cell lymphoma (SADAL) and liposarcoma (SEAL), among others. Additional Phase 1, Phase 2 and Phase 3 studies are ongoing or currently planned, including multiple studies in combination with one or more approved therapies in a variety of tumor types to further inform the Company's clinical development priorities for selinexor. In addition to single-agent and combination activity against a variety of human cancers, SINE™ compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses and wound-healing. Karyopharm, which was founded by Dr. Sharon Shacham, currently has five investigational programs in clinical or preclinical development. For more information, please visit [www.karyopharm.com](http://www.karyopharm.com).

Velcade® is a registered trademark of Takeda Pharmaceutical Company Limited

#### **Contacts:**

##### **Investors:**

Kimberly Minarovich  
(646) 368-8014  
kimberly@argotpartners.com

Gus Jenkins  
(646) 351-0167  
gus@argotpartners.com